GALT · Galectin Therapeutics Inc
United States · RS rating 49 · As of 2026-10-14
| Price | 3.64 USD |
|---|---|
| 1-day change | -1.4% |
| RS rating (overall / 1M / 3M / 12M) | 49 / 50 / 26 / 22 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 25 / 24 / 22 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -75.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +44.1% |
| Market cap (USD) | $156.0M |